One of Shire’s top pipeline prospects fails a PhII study among preemies
A couple of years ago, when new Shire CEO Flemming Ornskov was selling a bright future to investors, he carefully singled out SHP607 as one of the company’s top experimental drugs, on track to earn more than $500 million in annual sales by 2020.
But he may have to revisit that estimate after reporting this morning that the protein replacement therapy failed the primary endpoint of reducing the severity of retinopathy of prematurity.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.